Navigation Links
New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
Date:10/15/2007

property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com

GIULIANI SpA

Giuliani SpA, founded in 1889, is a privately owned specialty biopharmaceutical company strategically focused in gastroenterology and dermatology. It is currently marketing proprietary products for the treatment and management of ulcerative colitis, Crohn's disease, food intolerances and dermatological disorders. Giuliani's R&D pipeline includes new chemical entities and biotechnological products targeted to treat inflammatory and autoimmune diseases.

COSMO Pharmaceuticals SpA

Cosmo is a specialty pharma company that aims to become a global leader in optimized therapies for certain gastrointestinal diseases. The company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as ulcerative colitis and Crohn's disease, and colon infections. Cosmo's most advanced development product is LIALDA(TM)/ MEZAVANT(TM), a treatment for ulcerative colitis that is licensed globally to Giuliani and Shire Pharmaceuticals. Cosmo's proprietary MMX Technology is at the core of the company's product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. For further information on Cosmo, please visit the Company's website: http://www.cosmopharmaceuticals.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-l
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
10. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
11. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...s Potential Biomarkers -- for Lung Cancer Diagnosi...With Cancer of Unknown Primary ...fy Cancer Types With High Sensitivity and, Speci...ment of Cancer Results of microRNA Signature to I...racy Exceeding 90% and Specificity of 99%, REHOVO...
(Date:5/15/2008)...KE, N.J., May 15 /- Eisai Corporation...m 16 clinical data abstracts about,compounds in th...nd,preclinical oncology research have been accepte...he American Society of Clinical Oncology (ASCO),t...., A wide variety of abstracts on Eisai marketed ...
(Date:5/15/2008)...Presented at ASCO Showed Acceptable Tolerability P...and 4 Neuropathy, WOODCLIFF LAKE, N.J., May 15 /P... agent eribulin mesylate (E7389) demonstrated acti...ith locally advanced or metastatic,breast cancer, ...inical,trial. The study also suggests that eribuli...
(Date:5/15/2008)... N.J., May 15 /- Sanofi-ave... that findings from the,landmark ATHENA study show...r the treatment of patients with atrial fibrillati...vascular hospitalizations or death from any,cause ... meeting the study,primary endpoint. The ATHENA re...
Breaking Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Anxiety linked to newly diagnosed DCIS patients overestimation of breast cancer risks 11720 1Anxiety linked to newly diagnosed DCIS patients overestimation of breast cancer risks 11720 2Precancerous Breast Lesions Cause Unnecessary Worry 11716 1Precancerous Breast Lesions Cause Unnecessary Worry 11716 2Precancerous Breast Lesions Cause Unnecessary Worry 11716 3Precancerous Breast Lesions Cause Unnecessary Worry 11716 4Kaiser Permanente Approves 2429 Million in Community Benefit Grants 11713 1Kaiser Permanente Approves 2429 Million in Community Benefit Grants 11713 2Kaiser Permanente Approves 2429 Million in Community Benefit Grants 11713 3Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 11709 1Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 11709 2
(Date:5/16/2008)...edicine is in a precipitous decline, David C. Dale...hysicians (ACP), today joined with leading repres...ll for comprehensive reforms to attract, recruit a...e physicians. , During a panel discussion of th...Dale and other panelists spoke about the challenge...
(Date:5/16/2008)...wswire/- "Huh, what did you,say?" is a phrase bein...hildren. More than 30 million Americans, that is 1...nd the numbers are growing at a dramatic rate.,Thi...me form of hearing,loss. An effort to bring more a...at led Kathlyn Maguire, who has profound hearing l...
(Date:5/16/2008)...Million for Life-threatening,Disease, BETHESDA, M...early,every state will raise funds for cystic fibr...ting in GREAT STRIDES, the largest national CF,fun... today., May is National Cystic Fibrosis Awarenes...etic disease that causes fatal lung infections and...
(Date:5/16/2008)...10,000 Sensual O Condom Packs Donation Marks the ... LOS ANGELES, May 16 /PRNewswire/ -- On Saturday, ...wn best for his hit song "Everybody in the Club,Ge...Institute (UHI) with,10,000 Sensual O Vibrating Co...ng made to promote the launch of the Association f...
Breaking Medicine News(10 mins):Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Everybody in the Club Scream O! 2
...eghalaya so far this year, state Health minister E... to a calling attention notice, Marak said 11 deat...South Garo, six from East Garo Hills, nine died in...hasi and Ri-Bhoi district reported three deaths. T...
...r C. Divakaran Wednesday confirmed that pig fever ...igs at a private farminwayanad//. This is believed...he country. "Pig fever was ascribed to the death ...inary Research Institute in Uttar Pradesh after sa...
...ause heat is capable of relieving pain, say resear... use of DNA technology//, scientists were able to ...ells. When the heat is on, it has a pain relievin...s of heat for pain relief on par with a pain kille...
...exander Downer has sanctioned $17 million to take ...on of HIV-AIDS//, tuberculosis and malaria. To quo...re than half a million people to be treated with a...an $1.4 million people to be treated for tuberculo...
Other Medicine News:
Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens.
...ade; hydrophilic acrylic IOL is the newest advance...e patient and surgeon in mind. Its unique one-piec...rosslinked with PMMA haptics to provide superb con...e and biocompatibility. The high memory lathe-cut ...
FZ60 : the 1st monobloc hard & soft IOL. Thanks to an exclusive and patented process : the selective polymerisation, IOLTECH designed the first single piece rigid & soft IOL : the FZ60. This technolo
TRIPODE Hydrophilic Acrylic Lens.
Medicine Products: